Clinical Trial

Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2, randomized, multicenter study in adult and adolescent participants with asthma and type 2 inflammation
Protocol Amendment History 8 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-24
notable Primary completion pushed: 2026-06 -> 2026-07-13 2026-06-24
minor Completion pushed: 2026-07 -> 2026-08-10 2026-06-24
notable Trial sites expanded: 52 -> 59 locations 2026-06-13
notable Trial sites expanded: 49 -> 52 locations 2026-04-28
notable Primary completion pushed: 2026-04 -> 2026-06 2026-04-28
minor Completion pushed: 2026-05 -> 2026-07 2026-04-28
notable Trial sites expanded: 46 -> 49 locations 2026-04-01
Trial Details
NCT Number NCT06940141
Lead Sponsor Connect Biopharm LLC
Conditions Asthma Acute
Enrollment 160 participants
Start Date 2025-08-08
Primary Completion 2026-07-17 (estimated)
Study Completion 2026-08-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-06